Čájehuvvojit 1 - 3 oktiibuot 3 bohtosis ohcui M.R. Cooperberg', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Defining intermediate-risk prostate cancer suitable for active surveillance with PSA 10-20ng/ml: Pathological outcome analysis of a population-level dataset

    Defining intermediate-risk prostate cancer suitable for active surveillance with PSA 10-20ng/ml: Pathological outcome analysis of a population-level dataset Dahkki P.E. Lonergan, C.W. Jeong, S.L. Washington, A. Herlemann, P.R. Carroll, M.R. Cooperberg

    Almmustuhtton 2020-07-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer

    Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer Dahkki P.E. Lonergan, S.L. Washington, S. Zhao, J.E. Cowan, H.G. Nguyen, K. Shinohara, M.R. Cooperberg, P.R. Carroll

    Almmustuhtton 2020-07-01
    Viečča ollesdeavstta
    Artihkal
  3. 3
    Clinical utility of 4Kscore, ExosomeDx and SelectMDx and magnetic resonance imaging for the early detection of high-grade prostate cancer

    Clinical utility of 4Kscore, ExosomeDx and SelectMDx and magnetic resonance imaging for the early detection of high-grade prostate cancer Dahkki V. Fasulo, C.M. De la Calle, J.E. Cowan, P.E. Lonergan, M. Maggi, A.J. Gadzinsky, R.A. Yeoung, A. Saita, G. Lughezzani, R. Hurle, P. Casale, M.R. Cooperberg, K. Shinohara, P.R. Carroll, H.G. Nguyen

    Almmustuhtton 2020-10-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: